Recent developments in the medical and surgical treatment of melanoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent developments in the medical and surgical treatment of melanoma
Authors
Keywords
-
Journal
CA-A CANCER JOURNAL FOR CLINICIANS
Volume 64, Issue 3, Pages 171-185
Publisher
American Cancer Society
Online
2014-03-27
DOI
10.3322/caac.21224
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy?
- (2013) Dale Han et al. ANNALS OF SURGICAL ONCOLOGY
- Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma
- (2013) Dale Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
- (2013) C. Posch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sentinel Node Biopsy is Indicated for Thin Melanomas ≥0.76 mm
- (2012) Dale Han et al. ANNALS OF SURGICAL ONCOLOGY
- Sunitinib Therapy for Melanoma Patients withKITMutations
- (2012) David R. Minor et al. CLINICAL CANCER RESEARCH
- Melanoma prevention: are we doing enough? A Canadian perspective
- (2012) A.M. Joshua Current Oncology
- Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline
- (2012) Sandra L. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma
- (2011) Christy Y. Chai et al. ANNALS OF SURGICAL ONCOLOGY
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
- (2011) Richard W. Joseph et al. JOURNAL OF IMMUNOTHERAPY
- Surgical margins for melanoma in situ
- (2011) Joy H. Kunishige et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
- (2011) Peter Gillgren et al. LANCET
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
- (2010) D Handolias et al. BRITISH JOURNAL OF CANCER
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities
- (2009) Cedric E. Boesch et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US
- (2009) Georgia M. Beasley et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results of a matched pair analysis
- (2008) Dirk Rades et al. EUROPEAN JOURNAL OF CANCER
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started